Quick Answer
Amylyx Pharmaceuticals, Inc. reported Cash and Equivalents of $226.65 million for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $226.65M | +192.9% |
| 2024 | $77.39M | -54.5% |
| 2023 | $170.20M | +172.2% |
| 2022 | $62.53M | +24.6% |
| 2021 | $50.19M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $225.18M | +213.4% | +287.7% |
| June 30, 2025 | $58.09M | -22.6% | -2.8% |
| March 31, 2025 | $59.76M | -65.0% | -22.8% |
| December 31, 2024 | $77.39M | -54.5% | +7.7% |
| September 30, 2024 | $71.84M | -46.9% | -4.2% |
| June 30, 2024 | $75.00M | -69.7% | -56.0% |
| March 31, 2024 | $170.55M | +48.9% | +0.2% |
| December 31, 2023 | $170.20M | +172.2% | +25.8% |
- Amylyx Pharmaceuticals, Inc. showed an increase of +192.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s cash and equivalents has grown by 351.6% (from $50.19 million to $226.65 million).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: